Nanologica’s annual report for the financial year 2021 has been published and is now available on the company’s website.
The annual report can be downloaded from the company’s website www.nanologica.com (Investor Relations/Finansiella rapporter) and is also attached to the press release. An English translation of the annual report is expected to be available on the company’s website in mid-March.
For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Drug Development, Nanologica provides a unique drug delivery platform for local delivery of drugs to the lung with the aim of providing new treatment options for patients with lung diseases. In Chromatography, the company aims to make insulin available to more patients in need, by lowering the cost of manufacturing. Nanologica is headquartered in Södertälje and the company’s share (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.